JMJ Financial’s new Life Sciences Fund offers emerging life sciences companies expanded access to unsecured development capital. With a simple convertible note structure similar to our popular QuickLoans, eligible publicly-traded companies will receive up to $2,000,000 in initial funding, with follow-on funding totaling $4,000,000 or more.
While life sciences companies can significantly improve the human condition worldwide, they are faced with long, expensive development and approval runways. JMJ Financial has provided investment capital to many of these companies over the last 15 years, and our new fund will facilitate larger investments without sacrificing the speed and simplicity of our QuickLoan process.
Utilizing the firm’s investment capital, the new fund expedites decision-making and due diligence, applying the same simple, speedy documentation and funding process used in our revolutionary QuickLoans. For more information on the fund, contact us anytime.